Loading stock data…

Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

August 16, 2023 by Leave a Comment

Last Updated on August 16, 2023 by

[#item_full_content]

Related

Spread the word

You must log in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Email : support@biotechwinners.com

© 2022 · Bio Tech Winners · Privacy Policy

Generated by Feedzy

%d bloggers like this: